{"id":10505,"date":"2023-12-21T23:48:00","date_gmt":"2023-12-21T15:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10505"},"modified":"2024-12-03T22:03:00","modified_gmt":"2024-12-03T14:03:00","slug":"lees-pharmaceuticals-socazolimab-becomes-chinas-first-pd-l1-mab-for-cervical-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10505","title":{"rendered":"Lee&#8217;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer"},"content":{"rendered":"\n<p>Lee&#8217;s Pharmaceutical Holdings Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/0950:HKG\">HKG: 0950<\/a>) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/quote\/SRNE:OTCMKTS\">OTCMKTS: SRNE<\/a>), was the subject of a USD 46 million licensing agreement between Lee\u2019s Pharma and Sorrento in October 2014. The drug is involved in multiple clinical studies targeting various cancers, including recurrent or metastatic cervical cancer, high-grade osteosarcoma, urothelial carcinoma, and others. It received a breakthrough therapy designation (BTD) in China for the treatment of recurrent or metastatic cervical cancer in February 2021.<\/p>\n\n\n\n<p>Domestically, other drugs in development for cervical cancer in China include Akeso Biopharma\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>) cadonilimab (AK104), a bispecific antibody targeting PD-1 and CTLA-4, and Harbin Gloria Pharmaceuticals Co., Ltd\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/002437:SHE\">SHE: 002437<\/a>) PD-1 inhibitor zimberelimab. Additionally, Jiangsu Hengrui Pharmaceuticals Co., Ltd\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) PD-1 inhibitor camrelizumab in combination with famitinib, a multi-kinase inhibitor, and CSPC Pharmaceutical Group Ltd\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) PD-1 mAb enronsubaimab are awaiting regulatory decisions in China for cervical cancer treatment.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lee&#8217;s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[360,16,171,1787,2586,941,855,850,165,1786,18,15,852,1788,1785],"class_list":["post-10505","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-akeso-biopharma","tag-cancer","tag-cspc-pharmaceutical","tag-gloria-pharmaceuticals","tag-hengrui-pharmaceuticals","tag-hkg-0950","tag-hkg-1093","tag-hkg-9926","tag-lees-pharmaceutical","tag-otcmkts-srne","tag-pd-1-l1","tag-product-approvals","tag-sha-600276","tag-she-002437","tag-sorrento-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lee&#039;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento Therapeutics (OTCMKTS: SRNE), was the subject of a USD 46 million licensing agreement between Lee\u2019s Pharma and Sorrento in October 2014.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10505\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee&#039;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10505\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-21T15:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T14:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee&#8217;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer\",\"datePublished\":\"2023-12-21T15:48:00+00:00\",\"dateModified\":\"2024-12-03T14:03:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Akeso Biopharma\",\"Cancer\",\"CSPC Pharmaceutical\",\"Gloria Pharmaceuticals\",\"Hengrui Pharmaceuticals\",\"HKG: 0950\",\"HKG: 1093\",\"HKG: 9926\",\"Lee's Pharmaceutical\",\"OTCMKTS: SRNE\",\"PD-1\\\/L1\",\"Product approvals\",\"SHA: 600276\",\"SHE: 002437\",\"Sorrento Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10505#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10505\",\"name\":\"Lee's Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-21T15:48:00+00:00\",\"dateModified\":\"2024-12-03T14:03:00+00:00\",\"description\":\"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento Therapeutics (OTCMKTS: SRNE), was the subject of a USD 46 million licensing agreement between Lee\u2019s Pharma and Sorrento in October 2014.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10505\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10505#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee&#8217;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee's Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento Therapeutics (OTCMKTS: SRNE), was the subject of a USD 46 million licensing agreement between Lee\u2019s Pharma and Sorrento in October 2014.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10505","og_locale":"en_US","og_type":"article","og_title":"Lee's Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10505","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-21T15:48:00+00:00","article_modified_time":"2024-12-03T14:03:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10505#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10505"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee&#8217;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer","datePublished":"2023-12-21T15:48:00+00:00","dateModified":"2024-12-03T14:03:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10505"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Akeso Biopharma","Cancer","CSPC Pharmaceutical","Gloria Pharmaceuticals","Hengrui Pharmaceuticals","HKG: 0950","HKG: 1093","HKG: 9926","Lee's Pharmaceutical","OTCMKTS: SRNE","PD-1\/L1","Product approvals","SHA: 600276","SHE: 002437","Sorrento Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10505#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10505","url":"https:\/\/flcube.com\/?p=10505","name":"Lee's Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-21T15:48:00+00:00","dateModified":"2024-12-03T14:03:00+00:00","description":"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento Therapeutics (OTCMKTS: SRNE), was the subject of a USD 46 million licensing agreement between Lee\u2019s Pharma and Sorrento in October 2014.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10505#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10505"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10505#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee&#8217;s Pharmaceutical\u2019s Socazolimab Becomes China\u2019s First PD-L1 mAb for Cervical Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10505"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10505\/revisions"}],"predecessor-version":[{"id":16553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10505\/revisions\/16553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}